Gilead Sciences Inc GILD

Morningstar Rating
$170.26 +2.68 (1.60%)
View Full Chart

Company Report

Price vs Fair Value

GILD is trading at a LOCK|@X%bg< premium.
Price
$170.26
Fair Value
LOCK|yn
Uncertainty
LOCK|kw&%
1-Star Price
LOCK|%.v
5-Star Price
LOCK|&.T#
Economic Moat
LOCK|HD
Capital Allocation
LOCK|R##^F>

Bulls Say, Bears Say

Bulls

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Bears

Gilead's Yeztugo is a promising new HIV prevention drug, but it is unclear if markets outside the US will embrace this form of therapy.

News

Articles & Videos

Trading Information

Previous Close Price
$167.58
Day Range
$165.72–171.36
52-Week Range
$116.88–176.58
Bid/Ask
$167.68 / $170.25
Shares Outstanding
1.24B
Market Cap
$211.18B
Volume/Avg
6M / 6M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
6.84
Dividend Yield (Trailing)
1.91%
Dividend Yield (Forward)
1.93%
Dividend Payment Schedule
Mar, Jun, Sep, Dec
Total Yield
2.42%

Company Profile

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
17,000

Competitors

Valuation

Metric
GILD
ABBV
MRK
Price/Earnings (Normalized)
—33.19106.51
Price/Book Value
16.21—7.88
Price/Sales
6.847.865.27
Price/Cash Flow
14.3722.0916.02
Price/Earnings
GILD
ABBV
MRK

Financial Strength

Metric
GILD
ABBV
MRK
Quick Ratio
0.950.560.78
Current Ratio
1.380.871.35
Interest Coverage
−1.785.203.33
Quick Ratio
GILD
ABBV
MRK

Profitability

Metric
GILD
ABBV
MRK
Return on Assets (Normalized)
−0.60%16.61%2.53%
Return on Equity (Normalized)
−1.77%—7.02%
Return on Invested Capital (Normalized)
0.51%36.97%4.79%
Return on Assets
GILD
ABBV
MRK

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|%D<!&lT&LOCK|Tm!$1T
Johnson & Johnson
JNJ
LOCK|&^Mt$&WLOCK|C@$671B
AbbVie Inc
ABBV
LOCK|^?m$!<LOCK|PdM$518B
Roche Holding AG ADR
RHHBY
LOCK|Gt$>Q&PxLOCK|?Z$386B
Merck & Co Inc
MRK
LOCK|QW^$^^@LOCK|^X$353B
Novartis AG ADR
NVS
LOCK|@&<!?BjmLOCK|GL$300B
AstraZeneca PLC
AZN
LOCK|qt#%YLfLOCK|m@p$288B
Amgen Inc
AMGN
LOCK|<r&@@F!>LOCK|<&$248B
Novo Nordisk AS ADR
NVO
LOCK|!?K?H!%LOCK|#N$179B

Sponsor Center